STAT2 act a prognostic biomarker and associated with immune infiltration in kidney renal clear cell carcinoma

Renal clear cell carcinoma (KIRC) is a malignancy of the renal epithelial cells with poor prognosis. Notably, the JAK-STAT pathway mediates cell proliferation and immune response. Accumulating evidence suggests that STATs act as immune checkpoint inhibitors in various cancers. Nonetheless, the role of STAT2 in KIRC remains elusive. Herein, analyses were performed using a series of interactive web databases including Oncomine, GEPIA and TIMER. In sub-group analyses, STAT2 was upregulated at both the mRNA and protein levels in KIRC patients. Besides, KIRC patients with high STAT2 expression exhibited a poor overall survival. Moreover, Cox regression analysis revealed that STAT2 expression, nodal metastasis and clinical stage were independent factors affecting the prognosis of KIRC patients. There was a significant positive correlation between STAT2 expression, and the abundance of immune cells as well as the expression of immune biomarker sets. In addition, STAT2 was found to be implicated in immune response, cytokine-cytokine receptor interaction, and Toll-like receptor signaling pathways. Also, several cancer-related kinases, miRNAs, and transcription factors associated with STAT2 were identified. Conclusively, we revealed that STAT2 is a potential prognosis biomarker and associated with immune infiltration in kidney renal clear cell carcinoma. This study offers additional data that will help in further research on the roles of STAT2 protein in carcinogenesis.

[1]  Wenxing Gao,et al.  Comprehensive analysis of the prognostic and immunotherapeutic implications of STAT family members in human colorectal cancer , 2022, Frontiers in Genetics.

[2]  Chang-Shen Lin,et al.  High Expression of Interferon Pathway Genes CXCL10 and STAT2 Is Associated with Activated T-Cell Signature and Better Outcome of Oral Cancer Patients , 2022, Journal of personalized medicine.

[3]  Yuan Chang,et al.  LINC00997, a novel long noncoding RNA, contributes to metastasis via regulation of S100A11 in kidney renal clear cell carcinoma. , 2019, The international journal of biochemistry & cell biology.

[4]  U. Bommhardt,et al.  Beyond TCR Signaling: Emerging Functions of Lck in Cancer and Immunotherapy , 2019, International journal of molecular sciences.

[5]  Y. Ouyang,et al.  Immune infiltration in renal cell carcinoma , 2019, Cancer science.

[6]  F. Su,et al.  Expression profile and prognostic values of STAT family members in non-small cell lung cancer. , 2019, American journal of translational research.

[7]  P. Linsley,et al.  Renal Cell Carcinoma (RCC) Tumors Display Large Expansion of Double Positive (DP) CD4+CD8+ T Cells With Expression of Exhaustion Markers , 2018, Front. Immunol..

[8]  H. Yano,et al.  Prognostic value of PD-1 and PD-L1 expression in patients with metastatic clear cell renal cell carcinoma. , 2018, Urologic oncology.

[9]  M. Alsharedi,et al.  Check point inhibitors a new era in renal cell carcinoma treatment , 2018, Medical Oncology.

[10]  Jennifer R. Grandis,et al.  Targeting the IL-6/JAK/STAT3 signalling axis in cancer , 2018, Nature Reviews Clinical Oncology.

[11]  Jing Wang,et al.  LinkedOmics: analyzing multi-omics data within and across 32 cancer types , 2017, Nucleic Acids Res..

[12]  Qingjie Xian,et al.  Micro RNA-518 inhibits gastric cancer cell growth by inducing apoptosis via targeting MDM2. , 2018, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[13]  Jun S. Liu,et al.  TIMER: A Web Server for Comprehensive Analysis of Tumor-Infiltrating Immune Cells. , 2017, Cancer research.

[14]  Hua Yu,et al.  CTLA4 Promotes Tyk2-STAT3-Dependent B-cell Oncogenicity. , 2017, Cancer research.

[15]  B. Groner,et al.  Jak Stat signaling and cancer: Opportunities, benefits and side effects of targeted inhibition , 2017, Molecular and Cellular Endocrinology.

[16]  E. Daugas,et al.  Lyn and Fyn function as molecular switches that control immunoreceptors to direct homeostasis or inflammation , 2017, Nature Communications.

[17]  Chad J. Creighton,et al.  UALCAN: A Portal for Facilitating Tumor Subgroup Gene Expression and Survival Analyses , 2017, Neoplasia.

[18]  S. Pellegrini,et al.  Type I interferon‐enhanced IL‐10 expression in human CD4 T cells is regulated by STAT3, STAT2, and BATF transcription factors , 2017, Journal of leukocyte biology.

[19]  Guan-wu Li,et al.  The transcriptional STAT3 is a potential target, whereas transcriptional STAT5A/5B/6 are new biomarkers for prognosis in human breast carcinoma , 2017, Oncotarget.

[20]  Ting Wu,et al.  Tumor microenvironment and therapeutic response. , 2017, Cancer letters.

[21]  Qi Li,et al.  miR-296 inhibits the metastasis and epithelial-mesenchymal transition of colorectal cancer by targeting S100A4 , 2017, BMC Cancer.

[22]  J. L. Holloway,et al.  Genome-wide association analysis identifies genetic correlates of immune infiltrates in solid tumors , 2017, bioRxiv.

[23]  Gautier Koscielny,et al.  Open Targets: a platform for therapeutic target identification and validation , 2016, Nucleic Acids Res..

[24]  Patrick Danaher,et al.  Gene expression markers of Tumor Infiltrating Leukocytes , 2016, Journal of Immunotherapy for Cancer.

[25]  I. Cremer,et al.  Toll-like receptor stimulation in cancer: A pro- and anti-tumor double-edged sword. , 2017, Immunobiology.

[26]  A. Gratchev,et al.  Tumor Associated Macrophages in Kidney Cancer , 2016, Analytical cellular pathology.

[27]  S. Sousa,et al.  The role of tumour-associated macrophages in bone metastasis , 2016, Journal of bone oncology.

[28]  Xuetao Cao,et al.  Immunosuppressive cells in tumor immune escape and metastasis , 2016, Journal of Molecular Medicine.

[29]  J. Wolchok,et al.  Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies. , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

[30]  G. Freeman,et al.  Orchestration and Prognostic Significance of Immune Checkpoints in the Microenvironment of Primary and Metastatic Renal Cell Cancer , 2015, Clinical Cancer Research.

[31]  Yong Wang,et al.  The molecular mechanism of curcumol on inducing cell growth arrest and apoptosis in Jurkat cells, a model of CD4⁺ T cells. , 2014, International immunopharmacology.

[32]  W. Vainchenker,et al.  JAK/STAT signaling in hematological malignancies , 2013, Oncogene.

[33]  Benjamin E. Gross,et al.  Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal , 2013, Science Signaling.

[34]  Ya Cao,et al.  Detection of STAT2 in early stage of cervical premalignancy and in cervical cancer. , 2012, Asian Pacific journal of tropical medicine.

[35]  V. Jung,et al.  Analysis of serum microRNAs (miR-26a-2*, miR-191, miR-337-3p and miR-378) as potential biomarkers in renal cell carcinoma. , 2012, Cancer epidemiology.

[36]  Gary D. Bader,et al.  The GeneMANIA prediction server: biological network integration for gene prioritization and predicting gene function , 2010, Nucleic Acids Res..

[37]  N. Colburn,et al.  STAT2 Contributes to Promotion of Colorectal and Skin Carcinogenesis , 2010, Cancer Prevention Research.

[38]  Brad T. Sherman,et al.  Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources , 2008, Nature Protocols.

[39]  T. Barrette,et al.  ONCOMINE: a cancer microarray database and integrated data-mining platform. , 2004, Neoplasia.

[40]  J. Darnell,et al.  Signalling: STATs: transcriptional control and biological impact , 2002, Nature Reviews Molecular Cell Biology.

[41]  J. Darnell,et al.  Stat3 as an Oncogene , 1999, Cell.